Canceling Cancer’s Collaborators
Small-molecule Sb9 inhibitor targets both cancer and associated cells to suppress tumor growth in mice
James Strachan | | Quick Read
Some tumors – known as “cold tumors” – do not respond well to checkpoint inhibitors. To find out why, researchers from Brigham and Women’s Hospital examined a variety of tumors and found heavy expression of Sb9, which, in normal immune cells, acts as a shield against the cell’s own destructive enzymes (GrB).
Read the full article now
Log in or register to read this article in full and gain access to The Medicine Maker’s entire content archive. It’s FREE!
Or register now - it’s free!
You will benefit from:
- Unlimited access to ALL articles
- News, interviews & opinions from leading industry experts
- Receive print (and PDF) copies of The Medicine Maker magazine